Clinical Trial

A Study of Revumenib and Mezigdomide in People With Leukemia

Name: A Study of Revumenib and Mezigdomide in People With Leukemia — clinical trial record (NCT07356154)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-01-20.

Trial Details

NCT Number	NCT07356154
Lead Sponsor	Memorial Sloan Kettering Cancer Center
Conditions	Leukemia, Acute Leukemia, Relapse Leukemia, Refractory Leukemia, Refractory Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
Enrollment	52 participants
Start Date	2026-01-16
Primary Completion	2029-01-16 (estimated)
Study Completion	2029-01-16 (estimated)
Updated on ClinicalTrials.gov	2026-06-22